Loading…
Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature
Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of i...
Saved in:
| Published in: | Journal of oncology pharmacy practice 2020-01, Vol.26 (1), p.232-235 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423 |
| container_end_page | 235 |
| container_issue | 1 |
| container_start_page | 232 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 26 |
| creator | Stein, Jill Milhem, Mohammed Vaena, Daniel |
| description | Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity. |
| doi_str_mv | 10.1177/1078155219841108 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2319720508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155219841108</sage_id><sourcerecordid>2319720508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423</originalsourceid><addsrcrecordid>eNp1kEtLxDAUhYMozvjYu5KA62rSJk3rTgZfMOBGwV1Jk1snQ9vUJPWFP94MMyoIru7rnO_CQeiIklNKhTijRBSU85SWBaOUFFtoSpkQCSnTx-3Yx3Oyuk_QnvdLQkgh0mIXTTJS5pRlYoo-Z63pjZIttmNQtgOPZa9xsG9GmWDiaBs8yA87yN7UWOouyn0ABxpbJ9v2HZseKzf6Rdw01nXneCY9YAeDdWFNc_Bi4HVFCgvArYl2GUYHB2inka2Hw03dRw9Xl_ezm2R-d307u5gnKst5SADKXHEuG16KmrBaF5qrmgotGOMUdKaZrLXSuZa55iXVitVKAU9Z3EiWZvvoZM0dnH0ewYdqaUfXx5dVmtFSpISTIqrIWqWc9d5BUw3OdNK9V5RUq7irv3FHy_EGPNYd6B_Dd75RkKwFXj7B79d_gV-9cope</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2319720508</pqid></control><display><type>article</type><title>Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature</title><source>SAGE</source><creator>Stein, Jill ; Milhem, Mohammed ; Vaena, Daniel</creator><creatorcontrib>Stein, Jill ; Milhem, Mohammed ; Vaena, Daniel</creatorcontrib><description>Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155219841108</identifier><identifier>PMID: 30961437</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Carcinoma, Renal Cell - drug therapy ; Case crushing ; Case reports ; Chordoma - drug therapy ; Clinical outcomes ; Crushing ; Enzyme inhibitors ; Female ; Humans ; Inhibitor drugs ; Kidney cancer ; Kidney Neoplasms - drug therapy ; Literature reviews ; Oral administration ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Renal cell carcinoma ; Sarcoma ; Skull Base Neoplasms - drug therapy ; Soft tissue sarcoma ; Sulfonamides - administration & dosage ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Targeted cancer therapy ; Toxicity ; Vascular endothelial growth factor</subject><ispartof>Journal of oncology pharmacy practice, 2020-01, Vol.26 (1), p.232-235</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423</citedby><cites>FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423</cites><orcidid>0000-0001-6929-7496</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30961437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stein, Jill</creatorcontrib><creatorcontrib>Milhem, Mohammed</creatorcontrib><creatorcontrib>Vaena, Daniel</creatorcontrib><title>Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.</description><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Case crushing</subject><subject>Case reports</subject><subject>Chordoma - drug therapy</subject><subject>Clinical outcomes</subject><subject>Crushing</subject><subject>Enzyme inhibitors</subject><subject>Female</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Literature reviews</subject><subject>Oral administration</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Renal cell carcinoma</subject><subject>Sarcoma</subject><subject>Skull Base Neoplasms - drug therapy</subject><subject>Soft tissue sarcoma</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - adverse effects</subject><subject>Sulfonamides - therapeutic use</subject><subject>Targeted cancer therapy</subject><subject>Toxicity</subject><subject>Vascular endothelial growth factor</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLxDAUhYMozvjYu5KA62rSJk3rTgZfMOBGwV1Jk1snQ9vUJPWFP94MMyoIru7rnO_CQeiIklNKhTijRBSU85SWBaOUFFtoSpkQCSnTx-3Yx3Oyuk_QnvdLQkgh0mIXTTJS5pRlYoo-Z63pjZIttmNQtgOPZa9xsG9GmWDiaBs8yA87yN7UWOouyn0ABxpbJ9v2HZseKzf6Rdw01nXneCY9YAeDdWFNc_Bi4HVFCgvArYl2GUYHB2inka2Hw03dRw9Xl_ezm2R-d307u5gnKst5SADKXHEuG16KmrBaF5qrmgotGOMUdKaZrLXSuZa55iXVitVKAU9Z3EiWZvvoZM0dnH0ewYdqaUfXx5dVmtFSpISTIqrIWqWc9d5BUw3OdNK9V5RUq7irv3FHy_EGPNYd6B_Dd75RkKwFXj7B79d_gV-9cope</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Stein, Jill</creator><creator>Milhem, Mohammed</creator><creator>Vaena, Daniel</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0001-6929-7496</orcidid></search><sort><creationdate>202001</creationdate><title>Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature</title><author>Stein, Jill ; Milhem, Mohammed ; Vaena, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Case crushing</topic><topic>Case reports</topic><topic>Chordoma - drug therapy</topic><topic>Clinical outcomes</topic><topic>Crushing</topic><topic>Enzyme inhibitors</topic><topic>Female</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Literature reviews</topic><topic>Oral administration</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Renal cell carcinoma</topic><topic>Sarcoma</topic><topic>Skull Base Neoplasms - drug therapy</topic><topic>Soft tissue sarcoma</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - adverse effects</topic><topic>Sulfonamides - therapeutic use</topic><topic>Targeted cancer therapy</topic><topic>Toxicity</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stein, Jill</creatorcontrib><creatorcontrib>Milhem, Mohammed</creatorcontrib><creatorcontrib>Vaena, Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stein, Jill</au><au>Milhem, Mohammed</au><au>Vaena, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2020-01</date><risdate>2020</risdate><volume>26</volume><issue>1</issue><spage>232</spage><epage>235</epage><pages>232-235</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>30961437</pmid><doi>10.1177/1078155219841108</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-6929-7496</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2020-01, Vol.26 (1), p.232-235 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_journals_2319720508 |
| source | SAGE |
| subjects | Adult Aged Carcinoma, Renal Cell - drug therapy Case crushing Case reports Chordoma - drug therapy Clinical outcomes Crushing Enzyme inhibitors Female Humans Inhibitor drugs Kidney cancer Kidney Neoplasms - drug therapy Literature reviews Oral administration Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Renal cell carcinoma Sarcoma Skull Base Neoplasms - drug therapy Soft tissue sarcoma Sulfonamides - administration & dosage Sulfonamides - adverse effects Sulfonamides - therapeutic use Targeted cancer therapy Toxicity Vascular endothelial growth factor |
| title | Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A27%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20and%20toxicities%20of%20pazopanib%20administered%20orally%20in%20crushed%20form:%20Case%20reports%20and%20review%20of%20the%20literature&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Stein,%20Jill&rft.date=2020-01&rft.volume=26&rft.issue=1&rft.spage=232&rft.epage=235&rft.pages=232-235&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155219841108&rft_dat=%3Cproquest_cross%3E2319720508%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-ee96c55af597b04bd8d5cb17d74451ed3d4abdcd6da6d591dc4bcce5246daa423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2319720508&rft_id=info:pmid/30961437&rft_sage_id=10.1177_1078155219841108&rfr_iscdi=true |